XTX Topco Ltd Purchases 8,946 Shares of Blueprint Medicines Co. (NASDAQ:BPMC)

XTX Topco Ltd lifted its position in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 406.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 11,146 shares of the biotechnology company's stock after buying an additional 8,946 shares during the quarter. XTX Topco Ltd's holdings in Blueprint Medicines were worth $972,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of BPMC. Empirical Asset Management LLC purchased a new position in shares of Blueprint Medicines during the fourth quarter worth about $2,348,000. Stephens Inc. AR bought a new stake in Blueprint Medicines in the fourth quarter valued at approximately $321,000. Bank of New York Mellon Corp boosted its position in Blueprint Medicines by 2.4% during the 4th quarter. Bank of New York Mellon Corp now owns 303,432 shares of the biotechnology company's stock valued at $26,465,000 after buying an additional 7,101 shares during the period. KBC Group NV increased its position in shares of Blueprint Medicines by 63.9% in the fourth quarter. KBC Group NV now owns 2,625 shares of the biotechnology company's stock valued at $229,000 after acquiring an additional 1,023 shares during the period. Finally, Raymond James Financial Inc. purchased a new stake in shares of Blueprint Medicines during the fourth quarter worth about $21,104,000.

Wall Street Analyst Weigh In

Several research firms have weighed in on BPMC. Morgan Stanley assumed coverage on Blueprint Medicines in a report on Thursday, March 20th. They issued an "equal weight" rating and a $100.00 price objective for the company. Wolfe Research assumed coverage on shares of Blueprint Medicines in a research report on Tuesday, March 18th. They set an "outperform" rating on the stock. JMP Securities reaffirmed a "market outperform" rating and set a $125.00 target price on shares of Blueprint Medicines in a research note on Friday, February 14th. HC Wainwright reissued a "buy" rating and issued a $135.00 price target on shares of Blueprint Medicines in a research note on Friday, February 14th. Finally, Stephens reaffirmed an "overweight" rating and set a $140.00 price objective on shares of Blueprint Medicines in a research report on Thursday, January 2nd. Two investment analysts have rated the stock with a sell rating, six have given a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, Blueprint Medicines has an average rating of "Moderate Buy" and an average target price of $124.95.

Insider Activity at Blueprint Medicines

In related news, COO Christina Rossi sold 2,274 shares of the business's stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $110.14, for a total value of $250,458.36. Following the sale, the chief operating officer now owns 67,109 shares in the company, valued at approximately $7,391,385.26. The trade was a 3.28 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Kate Haviland sold 1,446 shares of the company's stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $110.24, for a total transaction of $159,407.04. Following the sale, the chief executive officer now owns 149,378 shares in the company, valued at $16,467,430.72. This represents a 0.96 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 24,358 shares of company stock valued at $2,583,187. Insiders own 4.21% of the company's stock.

Blueprint Medicines Price Performance

NASDAQ BPMC traded up $1.07 during trading hours on Monday, reaching $85.76. The company's stock had a trading volume of 246,205 shares, compared to its average volume of 766,677. The company has a quick ratio of 2.80, a current ratio of 2.85 and a debt-to-equity ratio of 1.15. Blueprint Medicines Co. has a 1 year low of $73.04 and a 1 year high of $121.90. The firm's 50-day moving average price is $88.61 and its 200-day moving average price is $93.27. The company has a market capitalization of $5.48 billion, a price-to-earnings ratio of -79.41 and a beta of 0.75.

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last announced its quarterly earnings results on Thursday, February 20th. The biotechnology company reported ($0.79) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.68) by ($0.11). Blueprint Medicines had a negative net margin of 13.19% and a negative return on equity of 77.49%. On average, equities research analysts predict that Blueprint Medicines Co. will post -1.28 EPS for the current fiscal year.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.